EUCTR2015-000307-10-NO进行中（未招募）不适用
AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies. - TREM
Oslo university hospital0 个研究点目标入组 150 人开始时间: 2015年3月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyEUCTR2015-000307-10-FIOslo university hospital150
进行中（未招募）
1 期
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyEUCTR2015-000307-10-SEOslo university hospital150
进行中（未招募）
1 期
ew targeted therapy in relapsed EGFR-mutated lung cancer previously treated with EGFR-inhibitorsocally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapyMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000307-10-DKOslo university hospital200
进行中（未招募）
2 期
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational StudiesTargeted TherapyLung CancerNCT02504346Oslo University Hospital200
进行中（未招募）
1 期
Optimalt tidspunkt for at skifte behandling fra Tarceva til Tagrisso.ung CancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2015-005637-47-DKDepartment of Oncology, Aarhus University Hospital50